Navigation Links
Hospira Supports Newly Introduced Biogenerics Legislation
Date:3/11/2009

-- Urges Quick Passage By Congress --

LAKE FOREST, Ill., March 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, announced today its enthusiastic support for the biogenerics bill co-sponsored by House Energy and Commerce Committee Chairman Henry Waxman, D-Calif., and Rep. Nathan Deal, R-Ga., and urges quick passage by Waxman's committee and the full Congress.

"The approval of biogenerics legislation would provide Americans access to more affordable biologic drugs and save the healthcare system billions of dollars," said Christopher Begley, chairman and chief executive officer, Hospira. "We look forward to working with Congress and the Obama administration to pass biogenerics legislation in 2009."

The Senate is expected to introduce similar legislation soon.

Although biogeneric drugs - generic versions of currently marketed biopharmaceuticals - are widely available in Europe and other parts of the world, they are not sold in the United States. The bipartisan bill introduced Wednesday, titled the "Promoting Innovation and Access to Life-Saving Medicine Act," would create a legislative pathway allowing the U.S. Food and Drug Administration (FDA) to approve safe and effective biogenerics to compete with existing biologic drugs, some of which currently cost more than $100,000 a year per patient. In Europe, biogeneric drugs have been shown to lower costs by around 20 percent.

The new legislation, like the original 1984 Hatch-Waxman legislation that provided access to safe and affordable generic drugs, would allow innovator companies - those that originally introduced biologic drugs - a five-year data exclusivity period for their products during which generic companies would not compete. Five years of exclusivity protects innova
'/>"/>

SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
2. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
3. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
4. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
5. Hospira Expands Board of Directors
6. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
7. Biogenerics Will Save Billions, Says Hospira CEO
8. Charlotte Anti-Aging Expo & Symposium Supports Free Clinics
9. BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women
10. Nonprofit Puts the Power to Cure Neurological Disease in the Hands of the Masses: Texting Technology Brings Awareness & Supports Research
11. Best Practice Database Supports Bio-Pharma Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... - Bioenterprise Corporation is pleased to announce that it will ... , PEI.  Bioenterprise has established a 3-year strategic ... the commercialization of agricultural technologies and innovations. ... They have been at the heart of agri-innovation in ... Dave Smardon , President & CEO of Bioenterprise Corporation.  ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
(Date:4/16/2015)... BETHESDA, Md. , April 16, 2015 /PRNewswire/ ... Bio"), a biotechnology company developing non-toxic DCVax® personalized ... has been included in the Loncar Cancer Immunotherapy ... help investors better track the immunotherapy field within ... founders have selected "the top 25 companies" in ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... 5 Experts from PAREXEL International Corporation (Nasdaq: ... services provider, will address important industry issues at ... being held from March 23 - 25, 2009 ... leaders will present on topics ranging from global ...
... BEACH, California and AMSTERDAM, March 5 ,Agendia, a ... the,appointment of Dr. Albert A. (Al) Luderer to ... Dr. Luderer has more than 30 years of ... therapeutic development. Currently, he,is the Chief Executive Officer ...
... WALTHAM, Mass., March 5 Proteon Therapeutics, Inc., announced ... Series B equity financing, led by MPM Capital on ... L.P. This announcement follows the initiation of a ... PRT-201, in patients with end stage renal disease undergoing ...
Cached Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Lugano, Switzerland, 14 September 2012 -- Ahead of the ... be released during the ESMO 2012 Congress, over 1,600 ... 2012 at 9:00 (CEST) to anticipate the flavor of ... emerging strategies set to combat cancer, signposting future directions ...
... have developed a method that for the first time ... proteins and subsequently remove them in a repeatable cycle., ... this week in the journal Nature Methods , ... naturally formed proteins in order to create better antibiotics, ...
... ,Boston (Sept. 14, 2012) Eye injuries in ... as weapons, tactics, technology and strategies have evolved. ... cause extensive damage areas not protected by body armor. ... Institute, Massachusetts Eye and Ear will convene in Boston, ...
Cached Biology News:Noteworthy studies at the ESMO 2012 Congress 2Noteworthy studies at the ESMO 2012 Congress 3Noteworthy studies at the ESMO 2012 Congress 4Noteworthy studies at the ESMO 2012 Congress 5Noteworthy studies at the ESMO 2012 Congress 6Noteworthy studies at the ESMO 2012 Congress 7Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3
... depletion cocktail is tailored to ... from suspensions of non-human primate ... separated using the StemSep (or ... selection system, achieving a 2.6 ...
... is tailored to highly enrich ... of non-human primate (Rhesus monkey) ... the StemSep compatible 0.5 Tesla) ... CD4+ T cell content of ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
...
Biology Products: